Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2017 Filed May 22, 2017 23:02 UTC |
Galbraith KennethDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000078 · wf-form4_149549412514927.xml · derivative · entry 1 Galbraith Kenneth · CIK 0001567045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:02 UTC |
Ferrante Karen JeanDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000077 · wf-form4_149549410690686.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:01 UTC |
HURWITZ EDWARDDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000076 · wf-form4_149549408648847.xml · derivative · entry 1 HURWITZ EDWARD · CIK 0001211840 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:01 UTC |
Costa Paulo FDirector
|
GrantStock Option (right to buy) · Derivative | 6,057 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000075 · wf-form4_149549406785537.xml · derivative · entry 2 Costa Paulo F · CIK 0001465928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,057 Underlying: Common Stock · 6,057 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. F2 · derivative.underlying_shares: At the election of the filing person, the option grant is issued in lieu of direct cash compensation of such person's annual retainer through the Company's non-employee director compensation program and will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:01 UTC |
Costa Paulo FDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000075 · wf-form4_149549406785537.xml · derivative · entry 1 Costa Paulo F · CIK 0001465928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| May 18, 2017 Filed May 22, 2017 23:01 UTC |
Fust Matthew KDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0001125345-17-000074 · wf-form4_149549404415241.xml · derivative · entry 1 Fust Matthew K · CIK 0001397266 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The option will vest and become exercisable in monthly, cumulative 1/12th increments (rounded upwards to whole shares) beginning one month from the date of grant. Read SEC document |
| April 28, 2017 Filed May 2, 2017 16:58 UTC |
SARAN ATULSVP & General Counsel
|
Tax withholdingCommon Stock | 1,862 | $21.61 | $40,237.82 |
DisclosureSEC source: 0001125345-17-000047 · wf-form4_149374429435733.xml · nonDerivative · entry 1 SARAN ATUL · CIK 0001591070 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,986 F1 · shares: Represents shares of common stock withheld to pay taxes upon vesting of RSU originally granted to the Reporting Person on April 28, 2014. The number of shares withheld was determined on April 28, 2017 based on the closing price of the Company's common stock on that day. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 20:15 UTC |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001125345-17-000044 · wf-form4_149271930447577.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,448 Underlying: Common Stock · 15,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 20:15 UTC |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
SaleCommon Stock | 15,000 | $20.00 | $300,000.00 |
DisclosureSEC source: 0001125345-17-000044 · wf-form4_149271930447577.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · date: The sales reported in this form 4 were effected pursuant to a Rule 10b-5 trading plan adopted by the reporting person on December 15, 2016. F2 · price: This transaction was executed in multiple trades at prices ranging from $20 to $20.03. F3 · balance_after: This amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which vest on 2/25/18. Read SEC document |
| April 19, 2017 Filed Apr 20, 2017 20:15 UTC |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
Exercise / conversionCommon Stock | 15,000 | $4.70 | $70,500.00 |
DisclosureSEC source: 0001125345-17-000044 · wf-form4_149271930447577.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:46 UTC |
Karrels JamesSVP, CFO and Secretary
|
GrantCommon Stock · Derivative | 55,000 | $20.53 Strike: $20.53 | $1,129,150.00 |
DisclosureSEC source: 0001125345-17-000035 · wf-form4_148728515999230.xml · derivative · entry 1 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:46 UTC |
Cilinski LynnVP, Controller and Treasurer
|
GrantCommon Stock · Derivative | 28,000 | $20.53 Strike: $20.53 | $574,840.00 |
DisclosureSEC source: 0001125345-17-000036 · wf-form4_148728517655735.xml · derivative · entry 1 Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:45 UTC |
SARAN ATULSVP & General Counsel
|
GrantCommon Stock · Derivative | 55,000 | $20.53 Strike: $20.53 | $1,129,150.00 |
DisclosureSEC source: 0001125345-17-000034 · wf-form4_148728514328800.xml · derivative · entry 1 SARAN ATUL · CIK 0001591070 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:45 UTC |
Spitznagel ThomasSr VP, BPD & Manufacturing
|
GrantCommon Stock · Derivative | 45,000 | $20.53 Strike: $20.53 | $923,850.00 |
DisclosureSEC source: 0001125345-17-000033 · wf-form4_148728512685526.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:45 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
GrantCommon Stock · Derivative | 55,000 | $20.53 Strike: $20.53 | $1,129,150.00 |
DisclosureSEC source: 0001125345-17-000032 · wf-form4_148728510924105.xml · derivative · entry 1 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:45 UTC |
Bonvini EzioSr VP, Research & CSO
|
GrantCommon Stock · Derivative | 67,500 | $20.53 Strike: $20.53 | $1,385,775.00 |
DisclosureSEC source: 0001125345-17-000031 · wf-form4_148728509153055.xml · derivative · entry 1 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:44 UTC |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
GrantCommon Stock · Derivative | 67,500 | $20.53 Strike: $20.53 | $1,385,775.00 |
DisclosureSEC source: 0001125345-17-000029 · wf-form4_148728505201545.xml · derivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 22:44 UTC |
Koenig ScottDirector · President and CEO
|
GrantCommon Stock · Derivative | 200,000 | $0.00 Strike: $20.53 | $0.00 |
DisclosureSEC source: 0001125345-17-000030 · wf-form4_148728507322958.xml · derivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-15 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| January 25, 2017 Filed Jan 26, 2017 21:36 UTC |
Karrels JamesSVP, CFO and Secretary
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 5,000 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001125345-17-000016 · wf-form4_148546658457123.xml · derivative · entry 2 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,516 Underlying: Common Stock · 5,000 shares Expires 2018-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2017 Filed Jan 26, 2017 21:36 UTC |
Karrels JamesSVP, CFO and Secretary
|
Exercise / conversionCommon Stock | 5,000 | $0.94 | $4,700.00 |
DisclosureSEC source: 0001125345-17-000016 · wf-form4_148546658457123.xml · nonDerivative · entry 1 Karrels James · CIK 0001587477 · SVP, CFO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Owned jointly with reporting person's wife. Read SEC document |
| January 24, 2017 Filed Jan 25, 2017 22:58 UTC |
Ferrante Karen JeanDirector
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.52 | $0.00 |
DisclosureSEC source: 0001125345-17-000014 · wf-form4_148538510247396.xml · derivative · entry 1 Ferrante Karen Jean · CIK 0001598502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: The option will vest 1/12th of the shares monthly, beginning on the first monthly anniversary of the grant date and will become fully exercisable 1 year from the date of grant (1/24/18). Read SEC document |
| January 24, 2017 Filed Jan 25, 2017 22:56 UTC |
Jackson Scott ThomasDirector
|
GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.52 | $0.00 |
DisclosureSEC source: 0001125345-17-000012 · wf-form4_148538496854009.xml · derivative · entry 1 Jackson Scott Thomas · CIK 0001566617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-24 F1 · derivative.exercise_date: The option will vest 1/12th of the shares monthly, beginning on the first monthly anniversary of the grant date and will become fully exercisable 1 year from the date of grant (1/24/18). Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:40 UTC |
Koenig ScottDirector · President and CEO
|
Exercise / conversionEmployee stock option (right to buy) · Derivative | 79,898 | $0.94 Strike: $0.94 | $75,104.12 |
DisclosureSEC source: 0001125345-17-000003 · wf-form4_148486200205855.xml · derivative · entry 4 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,898 shares Expires 2017-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:40 UTC |
Koenig ScottDirector · President and CEO
|
Exercise / conversionCommon Stock | 79,898 | $0.94 | $75,104.12 |
DisclosureSEC source: 0001125345-17-000003 · wf-form4_148486200205855.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2016 Filed Oct 21, 2016 23:19 UTC |
Bonvini EzioSr VP, Research & CSO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,349 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001552781-16-002007 · e00547_bonvini-form4.xml · derivative · entry 5 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,349 shares Expires 2020-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2016 Filed Oct 21, 2016 23:19 UTC |
Bonvini EzioSr VP, Research & CSO
|
Exercise / conversionCommon Stock | 5,349 | $0.94 | $5,028.06 |
DisclosureSEC source: 0001552781-16-002007 · e00547_bonvini-form4.xml · nonDerivative · entry 2 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2016 Filed Feb 8, 2017 22:18 UTC |
Bonvini EzioSr VP, Research & CSO
|
Exercise / conversionCommon Stock | 5,349 | $0.94 | $5,028.06 |
DisclosureSEC source: 0001125345-17-000018 · wf-form5_148659228598967.xml · nonDerivative · entry 1 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Due to clerical error, the reported amount of securities beneficially owned after the transaction on 10/19/16 and reported on a Form 4 on 10/21/16, was incorrect. The corrected amount now includes the disposal of 7550 shares which occurred on 9/22/15 and was reported on Form 5 on 2/12/16. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC |
Cilinski LynnVP, Controller and Treasurer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,994 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001552781-16-001976 · e00528_cilinski-form4.xml · derivative · entry 4 Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,994 shares Expires 2020-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC |
Cilinski LynnVP, Controller and Treasurer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,237 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001552781-16-001976 · e00528_cilinski-form4.xml · derivative · entry 3 Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,237 shares Expires 2019-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC |
Cilinski LynnVP, Controller and Treasurer
|
SaleCommon Stock | 6,231 | $29.28 | $182,443.68 |
DisclosureSEC source: 0001552781-16-001976 · e00528_cilinski-form4.xml · nonDerivative · entry 2 Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,923 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.755 to $29.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC |
Cilinski LynnVP, Controller and Treasurer
|
Exercise / conversionCommon Stock | 6,231 | $0.94 | $5,857.14 |
DisclosureSEC source: 0001552781-16-001976 · e00528_cilinski-form4.xml · nonDerivative · entry 1 Cilinski Lynn · CIK 0001587150 · VP, Controller and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001552781-16-001977 · e00529_wigginton-form4.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,254 Underlying: Common Stock · 10,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
SaleCommon Stock | 10,000 | $29.34 | $293,400.00 |
DisclosureSEC source: 0001552781-16-001977 · e00529_wigginton-form4.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.755 to $29.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:49 UTC |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
Exercise / conversionCommon Stock | 10,000 | $4.70 | $47,000.00 |
DisclosureSEC source: 0001552781-16-001977 · e00529_wigginton-form4.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016. Read SEC document |
| October 03, 2016 Filed Oct 19, 2016 21:20 UTC Amendment |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001552781-16-002003 · e00451_wigginton-form4a.xml · derivative · entry 3 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,254 Underlying: Common Stock · 10,000 shares Expires 2023-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Due to a clerical error, the reporting person is filing this amendment to the Form 4 originally filed on October 5, 2016 to correct the number of derivative securities beneficially owned following the reported transaction from 15,254 to 25,254. Read SEC document |
| October 03, 2016 Filed Oct 19, 2016 21:20 UTC Amendment |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
SaleCommon Stock | 10,000 | $29.34 | $293,400.00 |
DisclosureSEC source: 0001552781-16-002003 · e00451_wigginton-form4a.xml · nonDerivative · entry 2 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.755 to $29.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 03, 2016 Filed Oct 19, 2016 21:20 UTC Amendment |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
Exercise / conversionCommon Stock | 10,000 | $4.70 | $47,000.00 |
DisclosureSEC source: 0001552781-16-002003 · e00451_wigginton-form4a.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2016. Read SEC document |
| October 03, 2016 Filed Feb 8, 2017 22:27 UTC |
Wigginton Jon MarcSr VP, Clinical Dev. & CMO
|
SaleCommon Stock | 10,000 | $29.34 | $293,400.00 |
DisclosureSEC source: 0001125345-17-000020 · wf-form5_148659286027412.xml · nonDerivative · entry 1 Wigginton Jon Marc · CIK 0001587487 · Sr VP, Clinical Dev. & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · balance_after: Due to clerical error, the amount of securities beneficially owned after the transaction on 10/3/16 and reported on a Form 4 on 10/19/16, was incorrect. The corrected amount includes 30,000 Restricted Stock Units (RSU) acquired on 2/25/16 which vest on 2/25/18. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 22:11 UTC |
Risser Eric BlasiusSr VP & Chief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001552781-16-001951 · e00507_risser-form4.xml · derivative · entry 1 Risser Eric Blasius · CIK 0001587774 · Sr VP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-09-14 F1 · derivative.exercise_date: 12.5% of the option becomes exercisable on March 14, 2017 and the remaining 87.5% vests in 14 substantially equal quarterly installments thereafter. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 22:12 UTC |
Spitznagel ThomasSr VP, BPD & Manufacturing
|
GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001552781-16-001952 · e00508_spitznagel-form4.xml · derivative · entry 1 Spitznagel Thomas · CIK 0001675464 · Sr VP, BPD & Manufacturing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-09-14 F1 · derivative.exercise_date: 12.5% of the option becomes exercisable on March 14, 2017 and the remaining 87.5% vests in 14 substantially equal quarterly installments thereafter. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 22:10 UTC |
Bonvini EzioSr VP, Research & CSO
|
GrantEmployee Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001552781-16-001950 · e00506_bonvini-form4.xml · derivative · entry 1 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2026-09-14 F1 · derivative.exercise_date: 12.5% of the option becomes exercisable on March 14, 2017 and the remaining 87.5% vests in 14 substantially equal quarterly installments thereafter. Read SEC document |
| May 18, 2016 Filed Jan 19, 2017 21:40 UTC |
Koenig ScottDirector · President and CEO
|
OtherCommon Stock | 34,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000004 · wf-form5_148486201690358.xml · nonDerivative · entry 4 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Scott Koenig Family Irrevocable Trust Disclosed balance after: 167,782 F2 · kind: (2) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/18/16 was $21.06 per share. F2 · price: (2) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/18/16 was $21.06 per share. Read SEC document |
| May 18, 2016 Filed Jan 19, 2017 21:40 UTC |
Koenig ScottDirector · President and CEO
|
OtherCommon Stock | 34,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000004 · wf-form5_148486201690358.xml · nonDerivative · entry 2 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,265 F2 · kind: (2) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/18/16 was $21.06 per share. F2 · price: (2) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/18/16 was $21.06 per share. Read SEC document |
| May 17, 2016 Filed Jan 19, 2017 21:40 UTC |
Koenig ScottDirector · President and CEO
|
OtherCommon Stock | 79,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000004 · wf-form5_148486201690358.xml · nonDerivative · entry 3 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Scott Koenig Family Irrevocable Trust Disclosed balance after: 167,782 F1 · kind: (1) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/17/16 was $18.04 per share. F1 · price: (1) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/17/16 was $18.04 per share. Read SEC document |
| May 17, 2016 Filed Jan 19, 2017 21:40 UTC |
Koenig ScottDirector · President and CEO
|
OtherCommon Stock | 79,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000004 · wf-form5_148486201690358.xml · nonDerivative · entry 1 Koenig Scott · CIK 0001587514 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,265 F1 · kind: (1) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/17/16 was $18.04 per share. F1 · price: (1) Transaction was a transfer of direct ownership by reporting person to indirect ownership (Family Trust). Closing price on 5/17/16 was $18.04 per share. Read SEC document |
| February 11, 2016 Filed Oct 21, 2016 23:19 UTC |
Bonvini EzioSr VP, Research & CSO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,309 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001552781-16-002007 · e00547_bonvini-form4.xml · derivative · entry 4 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,349 Underlying: Common Stock · 1,309 shares Expires 2020-01-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction occurred on February 11, 2016. Due to an administrative error, the reporting person failed to timely file a Form 4 to report this transaction. Read SEC document |
| February 11, 2016 Filed Oct 21, 2016 23:19 UTC |
Bonvini EzioSr VP, Research & CSO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,653 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001552781-16-002007 · e00547_bonvini-form4.xml · derivative · entry 3 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,653 shares Expires 2021-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction occurred on February 11, 2016. Due to an administrative error, the reporting person failed to timely file a Form 4 to report this transaction. Read SEC document |
| February 11, 2016 Filed Oct 21, 2016 23:19 UTC |
Bonvini EzioSr VP, Research & CSO
|
Exercise / conversionCommon Stock | 11,962 | $0.94 | $11,244.28 |
DisclosureSEC source: 0001552781-16-002007 · e00547_bonvini-form4.xml · nonDerivative · entry 1 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction occurred on February 11, 2016. Due to an administrative error, the reporting person failed to timely file a Form 4 to report this transaction. Read SEC document |
| September 22, 2015 Filed Feb 8, 2017 22:18 UTC |
Bonvini EzioSr VP, Research & CSO
|
OtherCommon Stock | 7,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-17-000018 · wf-form5_148659228598967.xml · nonDerivative · entry 2 Bonvini Ezio · CIK 0001588365 · Sr VP, Research & CSO 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 7,550 F2 · balance_after: The 7550 shares disposed of on 9/22/15 were transferred to the Bonvini Family Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.